Vaxxinity (OTCMKTS:VAXX – Get Free Report) is anticipated to announce its resultson Wednesday, August 12th. Analysts expect Vaxxinity to post earnings of ($0.12) per share for the quarter.
Vaxxinity Stock Performance
OTCMKTS:VAXX opened at $0.00 on Wednesday. The stock’s 50-day moving average is $0.01. The company has a market cap of $12,675.00, a P/E ratio of -0.00 and a beta of -74.53. Vaxxinity has a 52-week low of $0.00 and a 52-week high of $0.20.
About Vaxxinity
Vaxxinity, Inc (NASDAQ: VAXX) is a clinical-stage biotechnology company focused on the development of peptide-based vaccines for serious diseases. Leveraging its proprietary synthetic peptide vaccine platform, the company designs antigens that co-present B-cell and T-cell epitopes to elicit robust and durable immune responses. Vaxxinity’s manufacturing collaborations support clinical-scale production and aim to facilitate broader commercial supply.
The company’s lead clinical programs include UB-311, an active immunotherapeutic vaccine candidate for Alzheimer’s disease currently in mid-stage trials, and UB-612, a multitope vaccine candidate for SARS-CoV-2 intended as a next-generation COVID-19 booster.
Further Reading
- Five stocks we like better than Vaxxinity
- Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.
